// App-Quantinova.ai

Su1931 : LONG-TERM EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN PATIENTS WITH Crohn's DISEASE: 5-YEAR CUMULATIVE EXPOSURE OF GEMINI 2 COMPLETERS ROLLING INTO THE GEMINI OPEN-LABEL EXTENSION STUDY

Researchers

Presenter

  • Edward V. Loftus

Principal Investigators

  • Jean Frederic Colombel

  • Ira Shafran

  • Sharon -Byrne

  • Parnia Geransar

  • Alessandro Previtali

  • Javaria M. Khalid

  • Arpeat Kaviya

  • Brian G. Feagan

  • William J. Sandborn

  • Bruce E. Sands

  • Silvio Danese

  • Geert R. D'Haens

  • Arthur Kaser

  • Remo Panaccione

  • David T. Rubin

Medical Centers

  • Department of Gynecologic Oncology, University of Calgary, Calgary, Alberta, Canada

  • Division of Gastroenterology, University of California San Diego Health System, La Jolla, California, United States

  • Gastrointestinal Immunopathology, Humanitas University , Italy, Milan, Italy

  • Department of clinical and experimental medicine, University Hospitals LEuven, Leuven, Belgium

  • Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

  • Pediatric Surgery, Academic Medical Center, Amsterdam, Netherlands

  • Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Rochester, Minnesota, United States

  • Shafran Gastroenterology Center, Winter Park, Florida, United States

  • Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, United States

  • Division of Gastroenterology and Hepatology, University of Cambridge, Cambridge, United Kingdom

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

Locations

  • Canada

  • Italy

  • Netherlands

  • United Kingdom

  • United States

  • Belgium

Companies

  • Takeda Pharmaceutica

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • Unknown


Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final